VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM.
Here's what investors need to know about the announcement.
Earnings
VistaGen Therapeutics beat estimated earnings by 28.57%, reporting an EPS of $-0.05 versus an estimate of $-0.07.
Revenue was up $44.30 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01, which was followed by a 4.0% increase in the share price the next day.
Here's a look at VistaGen Therapeutics's past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.06 | -0.05 | -0.05 | -0.05 |
| EPS Actual | -0.07 | -0.04 | -0.30 | -0.07 |
| Revenue Estimate | 260.00K | 380.00K | 230.00K | 210.00K |
| Revenue Actual | 358.00K | 354.10K | 441.90K | 313.60K |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
